SCHEMBL28846481

SCHEMBL28846481

COc1ccc(CN(C)S(=O)(=O)c2ccc(NC(=O)C3(O)CC3)s2)cc1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 6/20 0.47
▸ KMT2A Q03164 6/20 0.47
▸ POLB P06746 2/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ TNF P01375 1/20 0.42
▸ NOD2 Q9HC29 1/20 0.42
▸ NOD1 Q9Y239 1/20 0.42
▸ HDAC4 P56524 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40
▸ ACLY P53396 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ TAS2R14 Q9NYV8 2/20 0.38
▸ APLNR P35414 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ MAPT P10636 1/20 0.37
▸ TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28156749 0.81 CFTR (0.47) ALDH1A1HTT
SCHEMBL16338033 0.80 CFTR (0.56) MEN1KMT2APOLBRAB9ATNF
SCHEMBL28156807 0.78 MEN1 (0.53) MEN1KMT2APOLBRAB9ATNF
SCHEMBL28157292 0.74 L3MBTL1 (0.44) MEN1KMT2AALDH1A1SMN1; SMN2MAPT
SCHEMBL28156798 0.74 ALDH1A1 (0.33) KMT2ARAB9AHDAC6ALDH1A1HTT
SCHEMBL28846483 0.71 RAB9A (0.43) MEN1KMT2APOLBRAB9ATNF
SCHEMBL31045268 0.69 SMN1; SMN2 (0.57) MEN1KMT2AALDH1A1APLNRHTT
SCHEMBL28156802 0.67 HDAC4 (0.54) MEN1KMT2APOLBRAB9ATNF
SCHEMBL25347015 0.66 ALDH1A1 (0.48) MEN1KMT2AACLYALDH1A1TAS2R14
SCHEMBL28156726 0.65 CFTR (0.50) MEN1KMT2AALDH1A1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105531268-B Noval chemical compound and its pharmaceutical composition for treating cystic fibrosis 加拉佩格斯股份有限公司 2017-09-12 — — CN disclosed
Send feedback